Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB12066 in NAFLD
NCT02029586Phase 2Terminated
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Jan 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARQ761 in non-alcoholic fatty liver disease (NAFLD), sponsored by Yungjin Pharm. Co., Ltd.. Started Jan 2013; status: terminated.
02
Drugs
ARQ761
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02029586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029586.